Paolo Tarantino, 2025 Yvonne’s Top Voice’ Award Winner, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:

“What patients are eligible for adjuvant CDK4/6i?

We looked at this in ConcertAI: the approval of ribo doubled the patients eligible for adjuvant CDK4/6i (15% -> 30%) and provided an option for 10% of patients with N0 disease, those with the most aggressive cancers.”

CDK4/6

Title: Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2− early breast cancer: a United States Electronic Health Records database analysis

Journal: ESMO Open

Authors: P. Tarantino, H.S. Rugo, G. Curigliano, J.A. O’Shaughnessy, W. Janni, K. Jhaveri, J. Mouabbi, A. Brufsky, E. Hamilton, R. O’Regan, L. Santarsiero, M. Akdere, F. Ye, A. Scotchmer, S.L. Graff

CDK4/6

More posts featuring Paolo Tarantino on OncoDaily.

Paolo Tarantino: What Patients Are Eligible for Adjuvant CDK4/6 Inhibitors?

“What patients are eligible for adjuvant CDK4/6i?

We looked at this in ConcertAI: the approval of ribo doubled the patients eligible for adjuvant CDK4/6i (15% -> 30%) and provided an option for 10% of patients with N0 disease, those with the most aggressive cancers.”